Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion plans Uptravi launch following US FDA approval

Actelion plans Uptravi launch following US FDA approval

24th December 2015

Actelion has won approval from the US Food and Drug Administration (FDA) for Uptravi, a drug for treating pulmonary arterial hypertension (PAH).

It now plans to launch the drug in the US in January 2016, and is working "to obtain regulatory approval for Uptravi" in other markets around the world.

Actelion chief executive Jean-Paul Clozel described the approval as "another major landmark for Actelion".

"Together with our partners at Nippon Shinyaku we are proud to be able to offer an outstanding oral therapy targeting the prostacyclin pathway," he added.

Nippon Shinyaku originally discovered and synthesised the drug, which can be used to delay the progression of PAH and reduce the risk of people requiring hospitalisation for the condition.

Mr Clozel explained the green light for Uptravi gives Actelion an "unparalleled portfolio" of treatments for PAH – a form of high blood pressure affecting the lungs and heart that can be fatal if not addressed.ADNFCR-8000103-ID-801808895-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.